Proteomic Studies Coupled with RNAi Methodologies can Shed Further Light on the Downstream Effects of Telomerase in Glioma

REFERENCES

• Argyriou AA, Kalofonos HP. Molecularly targeted therapies for malignant gliomas. Mol Med 2009;15(3-4):115–122.
   PubMed Web of Science ®Google Scholar
• Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, Deen DF. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10(2):112–120.
   PubMed Web of Science ®Google Scholar
• Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T, Shervington L. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res 2007;1134(1):45–52.
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Hallmarks of telomeres in ageing research. J Pathol 2007;211(2):114–123.
   PubMed Web of Science ®Google Scholar
• Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996;56(3):645–650.
   PubMed Web of Science ®Google Scholar
• Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999;13(15):2091–2104.
   PubMed Web of Science ®Google Scholar
• Cong Y, Wright WE, Shay, JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66(3):407–425.
   PubMed Web of Science ®Google Scholar
• Mazzucchelli GD, Gabelica V, Smargiasso N, Fleron M, Ashimwe W, Rosu F, Pauw-Gillet, M.D., Riou J, Pauw, E.D. Proteome alteration induced by hTERT transfection of human fibroblast cells. Proteome Sci 2008;6(12):1–13.
   PubMedGoogle Scholar
• Shervington A, Cruickshanks N, Wright H, Atkinson-Dell, R., Lea R, Roberts G, Shervington, L. Glioma: what is the role of c-Myc, hsp90 and telomerase? Mol Cell Biochem 2006;283(1-2):1–9.
   PubMed Web of Science ®Google Scholar
• Cruickshanks N, Shervington L, Patel R, Munje C, Thakkar D, Shervington, A. Can hsp90alpha-Targeted siRNA combined with TMZ be a future therapy for glioma? Cancer Invest 2010;28(6):608–614.
   PubMed Web of Science ®Google Scholar
• Thakkar D, Shervington, A. Proteomics: the tool to bridge the gap between the facts and fables of telomerase. Crit Rev Oncog 2008;14(4):203–215.
   PubMedGoogle Scholar
• Shervington A, Patel, R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides 2008;18(4):365–374.
   PubMed Web of Science ®Google Scholar
• Shervington A, Pawar V, Menon S, Thakkar D, Patel, R. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep 2009;36(5):1181–1186.
   PubMed Web of Science ®Google Scholar
• Huang GP, Pan ZJ, Huang JP, Yang JF, Guo CJ, Wang YG, Zheng Q, Chen R, Xu YL, Wang GZ, Xi YM, Shen D, Jin J, Wang, J.F. Proteomic analysis of human bone marrow mesenchymal stem cells transduced with human telomerase reverse transcriptase gene during proliferation. Cell Prolif 2008;41:625–644.
   PubMed Web of Science ®Google Scholar
• Sobel, M.E. Differential expression of the 67 kDa laminin receptor in cancer. Semin Cancer Biol 1993;4(5):311–317.
   PubMed Web of Science ®Google Scholar
• Castronovo, V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 1993;13(1):1–30.
   PubMedGoogle Scholar
• Martignone S, Menard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue E, Andreola S, Rilke F, Colnaghi, M.I. Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 1993;85(5):398–402.
   Google Scholar
• Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner, R. Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol 2009;22(12):1600–1611.
   PubMed Web of Science ®Google Scholar
• Woo IS, Jang HS, Eun SY, Kim HJ, Ham SA, Kim HJ, Lee JH, Chang KC, Kim JH, Han CW, Seo, H.G. Ran suppresses paclitaxel-induced apoptosis in human glioblastoma cells. Apoptosis 2008;13(10):1223–1231.
   PubMed Web of Science ®Google Scholar
• Grabowski DT, Pieper RO, Futscher BW, Deutsch WA, Erickson LC, Kelley, M.R. Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer-human tumor cell lines. Carcinogenesis 1992;13(2):259–263.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhai H, Wang X, Wu H, Ning X, Han Y, Zhang D, Xiao B, Wu K, Fan, D. Multidrug-resistance-associated protein MGr1-Ag is identical to the human 37-kDa laminin receptor precursor. Cell Mol Life Sci 2002;59(9):1577–1583.
   PubMed Web of Science ®Google Scholar
• Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage, H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 1998;37(3):105–116.
   PubMedGoogle Scholar
• Zhang JT, Liu, Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 2007;33(8):741–756.
   PubMed Web of Science ®Google Scholar
• Rush MG, Drivas G, D'Eustachio, P. The small nuclear GTPase Ran: how much does it run? Bioessays 1996;18(2):103–112.
   PubMed Web of Science ®Google Scholar
• Rhee HJ, Kim GY, Huh JW, Kim SW, Na, D.S. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 2000;267(11):3220–3225.
   PubMedGoogle Scholar
• Condeelis J, Singer RH, Segall, J.E. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 2005;21:695–718.
   PubMed Web of Science ®Google Scholar
• Dizhoor, A. Site-directed and natural mutations in studying functional domains in guanylyl cyclase activating proteins (GCAPs). Adv Exp Med Biol 2002;514:291–301.
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Murata-Hori, M., Ishitobi S, Hosoya, H. Diphosphorylated MRLC is required for organization of stress fibers in interphase cells and the contractile ring in dividing cells. Cell Struct Funct 2001;26(6):677–683.
   PubMed Web of Science ®Google Scholar
• Tohtong R, Phattarasakul K, Jiraviriyakul A, Sutthiphongchai, T. Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain. Prostate Cancer Prostatic Dis 2003;6(3):212–216.
   PubMed Web of Science ®Google Scholar
• Feldner JC, Brandt, B.H. Cancer cell motility-on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272(2):93–108.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Condeelis, J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007;1773(5):642–652.
   PubMed Web of Science ®Google Scholar
• Peckham M, Miller G, Wells C, Zicha D, Dunn, G.A. Specific changes to the mechanism of cell locomotion induced by overexpression of beta-actin. J Cell Sci 2001;114:1367–1377.
   PubMed Web of Science ®Google Scholar
• Le PU, Nguyen TN, Drolet-Savoie, P., Leclerc N, Nabi, I.R. Increased beta-actin expression in an invasive moloney sarcoma virus-transformed MDCK cell variant concentrates to the tips of multiple pseudopodia. Cancer Res 1998;58(8):1631–1635.
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Wang HJ, Zalzal S, Nanci A, Nabi, I.R. Purification and characterization of beta-actin-rich tumor cell pseudopodia: role of glycolysis. Exp Cell Res 2000;258(1):171–183.
   PubMed Web of Science ®Google Scholar
• Andreeva L, Heads R, Green, C.J. Cyclophilins and their possible role in the stress response. Int J Exp Pathol 1999;80(6):305–315.
   PubMed Web of Science ®Google Scholar
• Bourquin JP, Stagljar I, Meier P, Moosmann P, Silke J, Baechi T, Georgiev O, Schaffner, W. A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II. Nucleic Acids Res 1997;25(11):2055–2061.
   PubMed Web of Science ®Google Scholar
• Bian XW, Xu JP, Ping YF, Wang Y, Chen JH, Xu CP, Wu YZ, Wu J, Zhou XD, Chen YS, Shi JQ, Wang, J.M. Unique proteomic features induced by a potential antiglioma agent, Nordy (dl-nordihydroguaiaretic acid), in glioma cells. Proteomics 2008;8(3):484–494.
   PubMed Web of Science ®Google Scholar
• Chen JX, Gao Y, Liu JW, Tian YX, Zhao J, Cui, X.Y. Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells. Int J Biochem Cell Biol 2005;37(6):1219–1231.
   Google Scholar
• Ando S, Tanabe K, Gonda Y, Sato C, Inagaki, M. Domain- and sequence-specific phosphorylation of vimentin induces disassembly of the filament structure. Biochemistry 1989;28(7):2974–2979.
   PubMed Web of Science ®Google Scholar
• Chou YH, Ngai KL, Goldman, R. The regulation of intermediate filament reorganization in mitosis. p34cdc2 phosphorylates vimentin at a unique N-terminal site. J Biol Chem 1991;266(12):7325–7328.
   PubMed Web of Science ®Google Scholar
• Huang TJ, Lee TT, Lee WC, Lai YK, Yu JS, Yang, S.D. Autophosphorylation-dependent protein kinase phosphorylates Ser25, Ser38, Ser65, Ser71, and Ser411 in vimentin and thereby inhibits cytoskeletal intermediate filament assembly. J Protein Chem 1994;13(6):517–525.
   PubMedGoogle Scholar
• Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi, K. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res 2009;29(1):279–281.
   Google Scholar
• Katsumoto T, Mitsushima A, Kurimura, T. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. Biol Cell 1990;68(2):139–146.
   Google Scholar
• Thoumine O, Ziegler T, Girard PR, Nerem, R.M. Elongation of confluent endothelial cells in culture: the importance of fields of force in the associated alterations of their cytoskeletal structure. Exp Cell Res 1995;219(2):427–441.
   PubMed Web of Science ®Google Scholar
• Wang N, Butler JP, Ingber, D.E. Mechanotransduction across the cell surface and through the cytoskeleton. Science 1993;260(5111):1124–1127.
   PubMed Web of Science ®Google Scholar
• Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson, P.H. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61(13):5168–5178.
   PubMed Web of Science ®Google Scholar
• Penuelas S, Noe V, Ciudad, C.J. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J 2005;272(3):696–710.
   PubMed Web of Science ®Google Scholar
• Trog D, Fountoulakis M, Friedlein A, Golubnitschaja, O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 2006;6(9):2924–2930.
   PubMed Web of Science ®Google Scholar
• Zhang MH, Lee JS, Kim HJ, Jin DI, Kim JI, Lee KJ, Seo, J.S. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. Mol Cell Biochem 2006;281(1–2):111–121.
   Google Scholar
• Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor, R.E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1996;15(4):507–525.
   Web of Science ®Google Scholar
• Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, Wang Y, Wu MC, Huang JF, Zeng WF, Sham JS, Yang M, Guan, X.Y. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23(1):298–302.
   PubMed Web of Science ®Google Scholar
• Trog D, Yeghiazaryan K, Schild HH, Golubnitschaja, O. Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment. Amino Acids 2008;34(4):539–545.
   PubMed Web of Science ®Google Scholar